A new vaccine against hepatitis B has passed all tests successfully and will soon appear in the market.
Sci-B-Vac trivalent hepatitis B vaccine by VBI Vaccines announced appeared to be more effective than GlaxoSmithKline’s Engerix-B vaccine which has been used since 1989.
The researchers claim that the new vaccine forms immunity against all three types of hepatitis B surface antigen - even in people who are not sensitive to ordinary vaccines, as well as in children born to mothers infected with hepatitis B.
Studies of the new vaccine were conducted on the territory of Russia as well and were completed successfully. According to forecasts, Russia will become the first European country to import new vaccine.